<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82067">
  <stage>Registered</stage>
  <submitdate>5/06/2007</submitdate>
  <approvaldate>5/06/2007</approvaldate>
  <actrnumber>ACTRN12607000301460</actrnumber>
  <trial_identification>
    <studytitle>The effects of nebulised N-acetylcysteine on sputum quality and diagnostic yield: a randomised, controlled clinical trial</studytitle>
    <scientifictitle>A randomised clinical trial to compare the efficacy of nebulized N-acetylcysteine and normal saline in improving sputum quality and diagnostic yield in patients with chest infections.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Sputum quality, chest infections</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single dose of 5 ml (200mg/ml) of nebulized N-acetylcysteine (intervention).</interventions>
    <comparator>Single dose of 5 ml of nebulized normal saline (control).</comparator>
    <control>Placebo</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of patients producing a sputum sample deemed good quality (presence of &gt;25 polymorphonuclear leukocytes and &lt;10 squamous cells per HPF [x1000 magnification field]) as identified by the microbiology laboratory technician</outcome>
      <timepoint>Measured within 2 days of sputum being obtained.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Proportion of all sputum samples which are positive for a predominant organism (ie. one type of organism clearly in greater numbers than other organisms on microscopy [Gram stain] or culture)</outcome>
      <timepoint>Measured approximately 1 week after sputum obtained.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Proportion of good quality sputum samples which are positive for a predominant organism (ie. one type of organism clearly in greater numbers than other organisms on microscopy [Gram stain] or culture)</outcome>
      <timepoint>Measured approximately 1 week after sputum obtained.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients for whom a change in antibiotic regimen is made as a result of the sputum microscopy and/or culture. </outcome>
      <timepoint>Measured approximately 1 week after sputum obtained.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse effects from NAC administration eg. bronchospasm, nausea. </outcome>
      <timepoint>Measured within 1 hour of administration of nebulised saline or N-acetyl cysteine.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Differential diagnosis inclusive of lower respiratory tract infection as determined by the treating physician (eg. cough, fever, pleuritic chest pain, dyspnoea, decreased breath sounds, bronchial breath sounds, crackles on auscultation) ·A sputum sample is to be collected in the ED.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Inability to co-operate or consent due to debility, significant illness, language barriers, altered consciousness (as determined by the ED or study staff)·Refusal to participate·Pregnancy or breast-feeding·Known allergy to NAC·Presence of significant hepatic or renal failure·Presence of other significant co-morbidities eg. HIV, immunocompromised, cystic fibrosis, bronchiectasis·CXR suggestive of TB·Recent hospital admission within the previous 14 days inclusively·Current treatment with &gt;10mg prenisolone daily for more than 1 month inclusively</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>A note containing each individual patients allocation will be inside a sealed envelope inside each study pack</concealment>
    <sequence>computer generated random numbers</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>All people invovled with this study will be blinded - patients, people administering the treatment, people assessing the outcomes (eg. adverse events, microscopy) and people analysing the results. Only when all results have been analysed will the randomisation code be broken and the nature of the drug administration will be revealed.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/08/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>190</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3084</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Austin Health</primarysponsorname>
    <primarysponsoraddress>145 Studley Road, Heidelberg, Victoria, 3084</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname> Austin Health</fundingname>
      <fundingaddress>145 Studley Road, Heidelberg, Victoria, 3084</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We believe that the use of N-acetylcysteine (a known mucolytic) will be useful in improving the diagnostic yield of sputum culture. If this hypothesis is proven, this agent can be recommend  for this purpose.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin health</ethicname>
      <ethicaddress />
      <ethicapprovaldate>20/08/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A/Prof David Taylor</name>
      <address>Emergency Department
Austin Hospital
Studley Road
Heidelberg VIC 3084</address>
      <phone>+61 3 9496 4883</phone>
      <fax>03 9496 3380</fax>
      <email>David.Taylor@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof David Taylor</name>
      <address>Emergency Department
Austin Hospital
Studley Road
Heidelberg, VIC 3084</address>
      <phone>+61 3 9496 4883</phone>
      <fax>03 9496 3380</fax>
      <email>David.Taylor@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>